Treatment with anti-ErbB2 antibodies

An antibody and a technology for use in the field of treating diseases characterized by overexpression of ErbB2, which can solve problems such as stimulating tumor growth

Inactive Publication Date: 2006-08-16
GENENTECH INC
View PDF24 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Different levels of tumor suppression were detected for the four antibodies, but one antibody (N28) consistently stimulated tumor growth

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Treatment with anti-ErbB2 antibodies
  • Treatment with anti-ErbB2 antibodies
  • Treatment with anti-ErbB2 antibodies

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0154] Materials and methods

[0155] Anti-ErbB2 monoclonal antibody. Anti-ErbB2 IgG specific for the ErbB2 extracellular domain was produced as described by Fendly et al. Cancer Res. 50:1550-1558 (1990) and WO89 / 06692 1 Kappa mouse monoclonal antibody 4D5. Briefly, NIH3T3 / HER2-3 was generated as described by Hudziak et al., Proc. Natl. Acad. Sci. (USA) 84:7159 (1987) 400 cells (each cell expresses about 1×10 5 ErbB2 molecules), the cells were harvested in phosphate buffered saline (PBS) containing 25 mM EDTA and used to immunize BALB / c mice. At the 0th, 2nd, 5th, and 7th weeks, the mice were intraperitoneally injected with 10 7 Cells in 0.5 ml PBS. At weeks 9 and 13, mice whose antiserum could immunoprecipitate 32p-labeled ErbB2 were injected intraperitoneally with WGA-purified ErbB2 membrane extracts. Then, 0.1 ml of the ErbB2 preparation was injected intravenously once, and the splenocytes were fused with the mouse myeloma cell line X63-Ag8.653. ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The present invention concerns the treatment of disorders characterized by the overexpression of ErbB2. More specifically, the invention concerns the treatment of human patients susceptible to or diagnosed with cancer overexpressing ErbB2 with a combination of an anti-ErbB2 antibody and a chemotherapeutic agent other than an anthracycline, e.g. doxorubicin or epirubicin.

Description

field of invention [0001] The present invention relates to methods of treating diseases characterized by overexpression of ErbB2. More specifically, the present invention relates to the treatment of patients predisposed to or diagnosed with ErbB2 overexpressing cancer with a combination of an anti-ErbB2 antibody and a chemotherapeutic agent instead of an anthracycline (such as doxorubicin or epirubicin). Background of the invention [0002] Proto-oncogenes encoding growth factors and growth factor receptors have been established to play important roles in the pathogenesis of various human malignancies, including breast cancer. It has been found that the human ErbB2 gene (erbB2, also known as her2 or c-erbB-2), is overexpressed in about 25-30% of human breast cancer patients, and this gene encodes the epidermal growth factor receptor (EGFR ) related 185kd transmembrane glycoprotein receptor (p185 HER2 ) (Slamon et al., Science, 235:177-182 [1987]; Slamon et al., Science, 24...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Patents(China)
IPC IPC(8): C07K16/32A61K39/395A61K31/335A61P35/00A61P35/04C12N15/09A61K38/00A61K45/06A61P43/00C12P21/08
CPCA61K38/00A61K39/39558A61K2039/505C07K2317/24A61K45/06A61K39/395A61K31/7068C07K16/32A61K31/337A61P1/04A61P1/16A61P1/18A61P11/00A61P13/08A61P13/10A61P13/12A61P15/00A61P25/00A61P35/00A61P35/02A61P35/04A61P37/02A61P43/00A61K31/335A61K2300/00
Inventor S·谢克V·E·佩顿苏珊.D.德斯蒙德-赫尔曼
Owner GENENTECH INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap